• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR XP PSA; PSA IMMUNOASSAY

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR XP PSA; PSA IMMUNOASSAY Back to Search Results
Model Number N/A
Device Problem Incorrect, Inadequate or Imprecise Result or Readings (1535)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Date 02/18/2014
Event Type  malfunction  
Event Description
Customer observed inconsistent advia centaur xp psa results between a neat sample and a diluted sample.There are no reports of altered or prescribed treatment based on the inconsistent results.There are no reports of adverse health consequences based on the inconsistent advia centaur xp psa results.
 
Manufacturer Narrative
The cause for the discordant advia centaur xp psa result may be due to the hook effect of the assay.There are no other reports of inconsistent results between neat and diluted samples at this site.No further evaluation of the device is required.The high-dose hook effect section of the instructions for use (ifu) states: "patient samples with high total psa levels can cause a paradoxical decrease in the rlus (high-dose hook effect).In this assay, patient samples with total psa levels as high as 10,000 ng/ml (10,000 ug/l) will assay greater than 100 ng/ml (100 ug/l)." the limitations section of the ifu states: "note: do not interpret levels of psa as absolute evidence of the presence or the absence of malignant disease.Before treatment, patients with confirmed prostate carcinoma frequently have levels of psa within the range observed in healthy individuals.Elevated levels of psa can be observed in patients with nonmalignant diseases.Measurements of psa should always be used in conjunction with other diagnostic procedures, including information from the patient's clinical evaluation.".
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ADVIA CENTAUR XP PSA
Type of Device
PSA IMMUNOASSAY
Manufacturer (Section D)
SIEMENS HEALTHCARE DIAGNOSTICS, INC.
tarrytown NY 10591
Manufacturer (Section G)
SIEMENS HEALTHCARE DIAGNOSTICS, INC
333 coney street
east walpole MA 02032
Manufacturer Contact
louise mclaughlin
333 coney street
east walpole, MA 02032
5086604381
MDR Report Key3674544
MDR Text Key4347302
Report Number1219913-2014-00069
Device Sequence Number1
Product Code MTF
Combination Product (y/n)N
Reporter Country CodeGM
PMA/PMN Number
P950021
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,User Facility
Reporter Occupation Health Professional
Remedial Action Inspection
Type of Report Initial
Report Date 02/18/2014
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date12/13/2014
Device Model NumberN/A
Device Catalogue Number06574155
Device Lot Number032253
Other Device ID NumberN/A
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 02/18/2014
Initial Date FDA Received03/12/2014
Was Device Evaluated by Manufacturer? No
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
-
-